BlackRock Japan’s Alexion Pharmaceuticals ALXN Stock Holding History

BlackRock Japan’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$36.7M	Buy	299,847 +10,937	+4%	+$1.34M	0.12%	200
2016 Q3	$35.4M	Buy	288,910 +3,042	+1%	+$392K	0.12%	196
2016 Q2	$33.4M	Buy	285,868 +2,673	+0.9%	+$379K	0.12%	201
2016 Q1	$39.4M	Sell	283,195 -43,106	-13%	-$6.33M	0.15%	158
2015 Q4	$62.2M	Buy	326,301 +18,994	+6%	+$3.32M	0.23%	94
2015 Q3	$48.1M	Sell	307,307 -5,831	-2%	-$1.06M	0.19%	123
2015 Q2	$56.6M	Buy	313,138 +74,641	+31%	+$12.9M	0.22%	106
2015 Q1	$41.3M	Sell	238,497 -13,727	-5%	-$2.48M	0.17%	147
2014 Q4	$46.7M	Buy	252,224 +21,000	+9%	+$3.89M	0.18%	136
2014 Q3	$38.3M	Buy	231,224 +14,595	+7%	+$2.4M	0.17%	144
2014 Q2	$33.8M	Sell	216,629 -21,650	-9%	-$3.42M	0.15%	157
2014 Q1	$36.2M	Buy	238,279 +14,450	+6%	+$2.3M	0.16%	151
2013 Q4	$29.7M	Sell	223,829 -16,781	-7%	-$2.01M	0.13%	178
2013 Q3	$27.9M	Buy	240,610 +10,144	+4%	+$1.11M	0.13%	181
2013 Q2	$21.3M	Buy	+230,466	New	+$22.2M	0.1%	240

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

BlackRock Japan's ALXN Position: Q4 2016 in Review

BlackRock Japan increased its Alexion Pharmaceuticals (ALXN) stake by 3.8% in Q4 2016, buying an estimated $1.34M and bringing the position to 299,847 shares worth $36.7M. The position accounts for 0.12% of the portfolio, ranked #200.

BlackRock Japan first reported a position in ALXN in Q2 2013 and has held it in 15 quarters since. The position peaked at $62.2M in Q4 2015. 548 funds tracked by Wall St. Rank hold ALXN as of Q4 2016.

BlackRock Japan held 299,847 shares of Alexion Pharmaceuticals worth $36.7M as of Q4 2016.
BlackRock Japan bought 10,937 Alexion Pharmaceuticals shares in Q4 2016, an estimated $1.34M.
Alexion Pharmaceuticals made up 0.12% of BlackRock Japan's portfolio in Q4 2016, its #200 holding.
BlackRock Japan first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
BlackRock Japan's Alexion Pharmaceuticals position peaked at $62.2M in Q4 2015.
548 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2016.

Based on BlackRock Japan's 13F filing for Q4 2016, filed 10 Feb 2017.